These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36457328)

  • 1. Untargeted metabolomics of pulmonary tuberculosis patient serum reveals potential prognostic markers of both latent infection and outcome.
    Wang X; Wu Z; Zeng J; Zhao Y; Zhang C; Yu M; Wang W; Chen X; Chen L; Wang J; Xu L; Zhou J; Tan Q; Wei W; Li Y
    Front Public Health; 2022; 10():962510. PubMed ID: 36457328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based identification of new serum biomarkers in patients with latent infection pulmonary tuberculosis.
    Li YX; Zheng KD; Duan Y; Liu HJ; Tang YQ; Wu J; Lin DZ; Zhang Z
    Medicine (Baltimore); 2022 Dec; 101(48):e32153. PubMed ID: 36482536
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Meng R; Dong W; Gao J; Lu C; Zhang C; Liao Q; Chen L; Wu H; Hu J; Wei W; Jiang Z
    Indian J Microbiol; 2022 Sep; 62(3):374-383. PubMed ID: 35974910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Expression of Activation Markers by Mycobacterium tuberculosis-specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection.
    Silveira-Mattos PS; Barreto-Duarte B; Vasconcelos B; Fukutani KF; Vinhaes CL; Oliveira-De-Souza D; Ibegbu CC; Figueiredo MC; Sterling TR; Rengarajan J; Andrade BB
    Clin Infect Dis; 2020 Nov; 71(8):1905-1911. PubMed ID: 31665254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of interferon (IFN)-γ inducible protein 10 (IP-10) as a biomarker for the discrimination of active and latent tuberculosis.
    Mamishi S; Mahmoudi S; Banar M; Hosseinpour Sadeghi R; Marjani M; Pourakbari B
    Mol Biol Rep; 2019 Dec; 46(6):6263-6269. PubMed ID: 31564016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection.
    Sun H; Pan L; Jia H; Zhang Z; Gao M; Huang M; Wang J; Sun Q; Wei R; Du B; Xing A; Zhang Z
    Front Microbiol; 2018; 9():1267. PubMed ID: 29951049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary metabolomic analysis to identify potential markers for the diagnosis of tuberculosis and latent tuberculosis.
    Deng J; Liu L; Yang Q; Wei C; Zhang H; Xin H; Pan S; Liu Z; Wang D; Liu B; Gao L; Liu R; Pang Y; Chen X; Zheng J; Jin Q
    Arch Biochem Biophys; 2021 Jun; 704():108876. PubMed ID: 33864753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia.
    Arroyo L; Marín D; Franken KLMC; Ottenhoff THM; Barrera LF
    BMC Infect Dis; 2018 Jan; 18(1):26. PubMed ID: 29310595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
    Metcalfe J; Bacchetti P; Esmail A; Reckers A; Aguilar D; Wen A; Huo S; Muyindike WR; Hahn JA; Dheda K; Gandhi M; Gerona R
    BMC Infect Dis; 2021 Jan; 21(1):99. PubMed ID: 33482745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M
    Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis: Common Questions and Answers.
    Hartman-Adams H; Gerbo RM; George S
    Am Fam Physician; 2022 Sep; 106(3):308-315. PubMed ID: 36126013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses.
    Amelio P; Portevin D; Hella J; Reither K; Kamwela L; Lweno O; Tumbo A; Geoffrey L; Ohmiti K; Ding S; Pantaleo G; Daubenberger C; Perreau M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosis patients in Korea.
    Park SH; Lee SJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Kim HJ; Menzies D
    Korean J Intern Med; 2016 May; 31(3):517-24. PubMed ID: 27052266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoniazid and Rifapentine Treatment Eradicates Persistent
    Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
    Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
    [No Abstract]   [Full Text] [Related]  

  • 17. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
    Cao J; Mi Y; Shi C; Bian Y; Huang C; Ye Z; Liu L; Miao L
    Biochem Biophys Res Commun; 2018 Mar; 497(2):485-491. PubMed ID: 29454961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of tuberculosis].
    Ben Amar J; Dhahri B; Aouina H; Azzabi S; Baccar MA; El Gharbi L; Bouacha H
    Rev Pneumol Clin; 2015; 71(2-3):122-9. PubMed ID: 25434510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of Pulmonary Tuberculosis and Detection of Resistance to Rifampin and Isoniazid through Direct Molecular Methods in Stool Samples.
    Yousef SA; AbdelRahim KA; Ahmed AO; Almaary KS; Mohamed AM
    Ann Clin Lab Sci; 2016 Dec; 46(6):616-621. PubMed ID: 27993874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.